Highlights from the literature

More treatment for obesity These are adult data but worthwhile reading. Tirzepatide, which is used in type two diabetes and is an insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist has not been examined in obese adults without diabetes. It is a once-a-week subcutaneous delivered medication. Jastreboff AM et al [N Engl J Med 2022; 387:205–216 DOI: 10.1056/NEJMoa2206038] have completed a phase three double-blind, randomised, controlled trial in 2539 adults with a body-mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes over 72 weeks. They have looked at three doses of tirzepatide or placebo, all given healthy lifestyle advice. The mean body weight was 104.8 kg at the beginning of the study (the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher). At 72 weeks there was significant change in weight for all the doses...
Source: Archives of Disease in Childhood - Category: Pediatrics Tags: Miscellanea Source Type: research